TITLE

Other News To Note

PUB. DATE
January 2012
SOURCE
BioWorld Today;1/19/2012, Vol. 23 Issue 12, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on the biopharmaceutical industry. An exclusive licensing agreement was signed between Applied Pharma Research SA and Labtec GmbH for the marketing and distribution of Setofilm. An orphan drug designation was granted by the European Medicines Agency (EMA) to Ceptaris Therapeutics Inc. for its investigational drug chlormethine gel. Pharmasset Inc. was acquired by Gilead Sciences Inc.
ACCESSION #
70705483

 

Related Articles

  • Other News To Note.  // BioWorld International;1/25/2012, Vol. 17 Issue 4, p3 

    This section offers news briefs from the pharmaceutical biotechnology industry. A Phase I combination trial is being considered by Active Biotech AB of Sweden for the study of tasquinimod in prostate cancer. It relates the exclusive licensing agreement signed by Applied Pharma Research SA of...

  • BioAlliance Gets Ondansetron License from APR and Labtec. Etheridge, James // BioWorld International;8/6/2008, Vol. 13 Issue 32, p3 

    The article reports on an exclusive licensing agreement signed by BioAlliance Pharma SA with Applied Pharma Research SA and its joint venture partner Labtech GmbH, for the commercialization rights in Europe of the thin-film formulation of ondansetron. The formulation was developed for the...

  • Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel.  // Biomedical Market Newsletter;1/21/2012, Vol. 21, p1 

    The article informs that the European Medicines Agency (EMA) has granted Orphan Drug Designation to investigational drug, chlormethine gel from Ceptaris Therapeutics Inc. The drug has been developed for the treatment of Cutaneous T-Cell Lymphoma (CTCL). The grant has been provided to promote the...

  • Other News To Note.  // BioWorld Today;1/25/2012, Vol. 23 Issue 16, p4 

    This section offers news briefs on the biotechnology industry. Active Biotech AB is planning to conduct a Phase I trial to examine tasquinimod (TASQ) in prostate cancer. A licensing agreement has been signed between Applied Pharma Research SA, Labtech GmbH and Norgine BV. Regnite (gabapentin...

  • arGentis wins European orphan drug designation for sclerosis drug.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p14 

    The article reports on the announcement by arGentis Pharmaceuticals LLC, a biopharmaceutical company, that the European Medicines Agency has accepted its product candidate ARG201 for the treatment of diffuse systemic sclerosis. It is noted that ARG201 is an immunotherapy that induces low dose...

  • APR Applied Pharma Research s.a. and Labtec GmbH Announce Ondansetron Oral Dispersible Film ("ODF") is Now Available for Licensing in Europe and Selected Non European Countries, after Having Received Marketing Authorization in Most Countries of Europe.  // Biomedical Market Newsletter;6/19/2011, p866 

    The article reports on the availability of Ondansetron Oral Dispersible Film (ODF) after Applied Pharma Research SA (APR) and Labtec GmbH have regained rights for marketing and commercialization of ODF. It states that ODF is available for licensing in Europe and selected non-European countries...

  • FDA grants marketing approval to VALCHLOR gel for cutaneous T-cell lymphoma.  // Hem/Onc Today;9/25/2013, Vol. 14 Issue 18, p29 

    The article focuses on the marketing approval granted by the U.S. Food and Drug Administration (FDA) to VALCHLOR mechlorethamine gel from Ceptaris for the topical treatment of stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

  • Other News To Note.  // BioWorld Today;9/21/2012, Vol. 23 Issue 184, p5 

    This section offers news briefs on the biopharmaceutical sector. A regulatory meeting was conducted by Biovest International Inc. with the European Medicines Agency about its personalized cancer vaccine BiovaxID for non-Hodgkin's lymphoma. A strategic licensing agreement was signed between Dyax...

  • Other News To Note.  // BioWorld Today;5/25/2012, p2 

    This section offers news briefs on the U.S. biopharmaceutical sector. The marketing authorization application submitted by Gilead Sciences Inc. for cobicistat was validated by the European Medicines Agency. A pre-investigational new drug meeting was completed by RetroSense Therapeutics Inc. with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics